Glioblastoma Foundation Inc
- Assets
- $1.8m
- Revenue
- $1.5m
- Investments
- $724.4k
- Employees
- 5
- Location
- Durham, NC
- Founding
- 06/2016
- Data as of
- 12/2022
- EIN
- 81-2849764
Organization Overview
Glioblastoma Foundation Inc is located in Durham, NC. The organization was established in 2016. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. As of 12/2022, Glioblastoma Foundation Inc employed 5 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Glioblastoma Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Glioblastoma Foundation Inc generated $1.5m in total revenue. This organization has experienced exceptional growth, as over the past 5 years, it has increased revenue by an average of 36.2% each year . All expenses for the organization totaled $853.6k during the year ending 12/2022. You can explore the organizations financials more deeply in the financial statements section below.
Since 2019, Glioblastoma Foundation Inc has awarded 14 individual grants totaling $367,000. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
AS THE FIRST AND LEADING NATIONAL NONPROFIT DEVOTED TO GLIOBLASTOMA, THE MISSION OF THE GLIOBLASTOMA FOUNDATION IS TO FUND LEADING-EDGE RESEARCH FOR A CURE FOR GLIOBLASTOMA, PROVIDE PATIENT SUPPORT RESOURCES, AND RAISE AWARENESS OF THIS RARE, GRADE 4 BRAIN CANCER.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE RESEARCH ACHIEVEMENTS OF THE GLIOBLASTOMA FOUNDATION IN 2022 INVOLVED CONTINUING FUNDING FOR LEADING EDGE RESEARCH FOR TARGETED TREATMENTS FOR GLIOBLASTOMA, PROVIDING PATIENT SUPPORT RESOURCES FOR FAMILIES AND PATIENTS DIAGNOSED WITH GLIOBLASTOMA, AND RAISING AWARENESS OF THIS RARE GRADE 4 BRAIN CANCER. DURING THE 2022 YEAR WE CONTINUED TO FUND RESEARCH FOR THE COMBINATION DRUG THERAPY OF LOMUSTINE AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS, FUNDED RESEARCH INTO PATIENT AND CAREGIVER QUALIFY OF LIFE AFTER DIAGNOSIS RESEARCH, AND A TARGETED RESEARCH STUDY ON GLIOBLASTOMA CANCER CELL METABOLISM PROCESSES AND DRUGS TO STOP GLIOBLASTOMA CELL GROWTH. WE ALSO MOVED FORWARD ON OUR GOAL TO MANUFACTURE LOMUSTINE AT A REDUCED RATE FOR PATIENTS BY PARTNERING WITH CONTINUITY PHARMA IN THE PRODUCTIVE OF LOMUSTINE ACTIVE PHARMACEUTICAL INGREDIENT. THIS PROJECT IS CURRENTLY UNDERWAY TO BRING LOMUSTINE TO PATIENTS AT A LOWER COST. WE ALSO CONTINUED OUR PATIENT PROGRAMS TO PROVIDE CLINICAL TRIALS MATCHING TO PATIENTS AFTER A GLIOBLASTOMA DIAGNOSIS AND CONTINUED TO HOST OUR AWARD-WINNING SUPPORT GROUP FOR PATIENTS AND CAREGIVERS, CALLED THE GLIOBLASTOMA SUPPORT CIRCLE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Neelam Kwatra President | OfficerTrustee | 4 | $0 |
Madan Kwatra Treasurer/secretary | OfficerTrustee | 4 | $0 |
Gita Kwatra CEO | OfficerTrustee | 40 | $202,250 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,513,382 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,513,382 |
| Total Program Service Revenue | $0 |
| Investment income | $14,333 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$56,165 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $1,471,550 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $180,000 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $192,826 |
| Compensation of current officers, directors, key employees. | $9,639 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $69,943 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $132,316 |
| Fees for services: Accounting | $0 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $91,507 |
| Office expenses | $53,161 |
| Information technology | $29,229 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $49,240 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $11,614 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $1,058 |
| Insurance | $0 |
| All other expenses | $679 |
| Total functional expenses | $853,578 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $1,034,846 |
| Pledges and grants receivable | $18,250 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $3,896 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $724,407 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $1,781,399 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $1,781,399 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $1,781,399 |
Grants Awarded
Over the last fiscal year, Glioblastoma Foundation Inc has awarded $180,000 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PURPOSE: GLIOBLASTOMA RESEARCH | $50,000 |
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PURPOSE: GLIOBLASTOMA RESEARCH | $40,000 |
DUKE UNIVERSITY HOSPITAL PURPOSE: GLIOBLASTOMA RESEARCH | $90,000 |